Pub Date : 2025-06-20DOI: 10.1038/s41585-025-01055-1
Daniel J. Benedetti, Nicholas G. Cost, Peter F. Ehrlich, Nicholas Evageliou, Elizabeth Fialkowski, Lauren N. Parsons, Kelly L. Vallance, Lindsay A. Renfro, Andrew L. Hong, Jennifer H. Aldrink, Luke Pater, Arnold C. Paulino, Jesse K. Sandberg, Ethan A. Smith, Amy L. Treece, Jeffrey S. Dome, James I. Geller, Elizabeth A. Mullen
Patients with Wilms tumour have benefited from the results of decades of large collaborative clinical trials, leading to improved care. In the National Wilms Tumor Study Group and now Children’s Oncology Group (COG) trials, risk stratification evolved and expanded with each generation of studies and, therefore, ensuring that each patient receives the appropriate therapy has become increasingly complex. A new risk stratification system has been developed that forms the basis of the upcoming COG favourable-histology Wilms tumour (FHWT) study. Topics of diagnostic and prognostic uncertainty, such as the findings of tumour pulmonary emboli or extra-abdominal lymphadenopathy at diagnosis, will be integrated into the central review determination of staging of FHWT by committee consensus to facilitate clinical classification for therapeutic studies. Clear documentation of the elements of current risk stratification are of particular importance as refinement of the classification of patients with FHWT continues in an effort to optimize research, personalize treatment and provide an educational resource. In this Consensus Statement, the authors describe the details of the evolution of the risk-based treatment of favourable-histology Wilms tumour (FHWT) and outline the rationale for the new risk stratification that will be used in the now open Children’s Oncology Group therapeutic trial for FHWT, AREN2231.
{"title":"Updated favourable-histology Wilms tumour risk stratification: rationale for future Children’s Oncology Group clinical trials","authors":"Daniel J. Benedetti, Nicholas G. Cost, Peter F. Ehrlich, Nicholas Evageliou, Elizabeth Fialkowski, Lauren N. Parsons, Kelly L. Vallance, Lindsay A. Renfro, Andrew L. Hong, Jennifer H. Aldrink, Luke Pater, Arnold C. Paulino, Jesse K. Sandberg, Ethan A. Smith, Amy L. Treece, Jeffrey S. Dome, James I. Geller, Elizabeth A. Mullen","doi":"10.1038/s41585-025-01055-1","DOIUrl":"10.1038/s41585-025-01055-1","url":null,"abstract":"Patients with Wilms tumour have benefited from the results of decades of large collaborative clinical trials, leading to improved care. In the National Wilms Tumor Study Group and now Children’s Oncology Group (COG) trials, risk stratification evolved and expanded with each generation of studies and, therefore, ensuring that each patient receives the appropriate therapy has become increasingly complex. A new risk stratification system has been developed that forms the basis of the upcoming COG favourable-histology Wilms tumour (FHWT) study. Topics of diagnostic and prognostic uncertainty, such as the findings of tumour pulmonary emboli or extra-abdominal lymphadenopathy at diagnosis, will be integrated into the central review determination of staging of FHWT by committee consensus to facilitate clinical classification for therapeutic studies. Clear documentation of the elements of current risk stratification are of particular importance as refinement of the classification of patients with FHWT continues in an effort to optimize research, personalize treatment and provide an educational resource. In this Consensus Statement, the authors describe the details of the evolution of the risk-based treatment of favourable-histology Wilms tumour (FHWT) and outline the rationale for the new risk stratification that will be used in the now open Children’s Oncology Group therapeutic trial for FHWT, AREN2231.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 11","pages":"775-788"},"PeriodicalIF":14.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41585-025-01055-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-18DOI: 10.1038/s41585-025-01060-4
Louise Lloyd
{"title":"Turning back time in the testes","authors":"Louise Lloyd","doi":"10.1038/s41585-025-01060-4","DOIUrl":"10.1038/s41585-025-01060-4","url":null,"abstract":"","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 7","pages":"409-409"},"PeriodicalIF":14.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-16DOI: 10.1038/s41585-025-01061-3
Louise Lloyd
{"title":"Pivotal role of PPARγ in UTO","authors":"Louise Lloyd","doi":"10.1038/s41585-025-01061-3","DOIUrl":"10.1038/s41585-025-01061-3","url":null,"abstract":"","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 7","pages":"409-409"},"PeriodicalIF":14.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144296008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-16DOI: 10.1038/s41585-025-01058-y
Raghav Khanna, Nicholas Raison, Alejandro Granados, Sebastien Ourselin, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi, Prokar Dasgupta
Quantum computing can revolutionize surgery by accelerating the training of artificial intelligence models on large, diverse datasets, advancing robotic autonomy and facilitating a detailed study of biological structures and materials on a very minute scale. Substantial technical, financial and regulatory challenges must be overcome for the successful implementation of quantum computing in urology.
{"title":"Quantum computing in surgery and urology — taking a quantum leap","authors":"Raghav Khanna, Nicholas Raison, Alejandro Granados, Sebastien Ourselin, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi, Prokar Dasgupta","doi":"10.1038/s41585-025-01058-y","DOIUrl":"10.1038/s41585-025-01058-y","url":null,"abstract":"Quantum computing can revolutionize surgery by accelerating the training of artificial intelligence models on large, diverse datasets, advancing robotic autonomy and facilitating a detailed study of biological structures and materials on a very minute scale. Substantial technical, financial and regulatory challenges must be overcome for the successful implementation of quantum computing in urology.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"23 1","pages":"2-3"},"PeriodicalIF":14.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-16DOI: 10.1038/s41585-025-01059-x
Maria Chiara Masone
{"title":"Acupuncture to reduce nocturia in survivors of prostate cancer","authors":"Maria Chiara Masone","doi":"10.1038/s41585-025-01059-x","DOIUrl":"10.1038/s41585-025-01059-x","url":null,"abstract":"","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 7","pages":"409-409"},"PeriodicalIF":14.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144296009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-09DOI: 10.1038/s41585-025-01054-2
Qian Tao (, ), Qian Zhang (, )
Mapping the N6-methyladenosine (m6A) transcriptome in prostate cancer has established its clinical potential value as a prognostic biomarker for this disease. A multidisciplinary approach that integrates genomics, transcriptomics, epitranscriptomics, proteomics and clinical oncology is essential to translate the intricacies of m6A modification into tangible benefits for patients
{"title":"Translating the m6A epitranscriptome for prostate cancer","authors":"Qian Tao \u0000 (, ), Qian Zhang \u0000 (, )","doi":"10.1038/s41585-025-01054-2","DOIUrl":"10.1038/s41585-025-01054-2","url":null,"abstract":"Mapping the N6-methyladenosine (m6A) transcriptome in prostate cancer has established its clinical potential value as a prognostic biomarker for this disease. A multidisciplinary approach that integrates genomics, transcriptomics, epitranscriptomics, proteomics and clinical oncology is essential to translate the intricacies of m6A modification into tangible benefits for patients","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 12","pages":"797-798"},"PeriodicalIF":14.6,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144238137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-06DOI: 10.1038/s41585-025-01047-1
Hannah E. Lyons, Andrew Peel, Macarena Gonzalez, Josh Deluao, Oluwabunmi Olatunji, Victoria Nikitaras, Nicole O. McPherson
Declining fertility, overlooked mental health, and reduced life expectancy underscore the urgent need for renewed attention to men’s health. A semen analysis, traditionally used to assess fertility, holds untapped potential as a tool for promoting lifestyle changes and preventing chronic diseases in men. Spermatogenesis is highly sensitive to environmental and lifestyle factors and can be an early indicator of overall health. Disruptions in this process can signal underlying systemic issues and predict long-term health risks, including cardiovascular disease and metabolic disorders. An increasing number of men seek to engage in preconception care, as fertility is closely tied to a man’s sense of masculinity, identity and aspirations for fatherhood. In this context, a semen analysis can be a powerful motivator to encourage healthy behaviours and proactive health management. By incorporating semen analysis into primary care, health care providers can leverage men’s desire for fatherhood as an entry point to discuss broader health concerns, such as mental well-being, nutrition and physical activity. This approach would address immediate reproductive health, and also promote long-term wellness, helping to reduce the burden of chronic disease in men. This Review discusses the association between semen parameters and men’s overall health, describing how these parameters can be influenced by lifestyle and environmental changes. Semen analysis is also presented as a potential tool to motivate men to undertake lifestyle changes to improve their reproductive and overall health.
{"title":"Unlocking the power of semen analysis in primary health care — a path to men’s health and lifestyle transformation","authors":"Hannah E. Lyons, Andrew Peel, Macarena Gonzalez, Josh Deluao, Oluwabunmi Olatunji, Victoria Nikitaras, Nicole O. McPherson","doi":"10.1038/s41585-025-01047-1","DOIUrl":"10.1038/s41585-025-01047-1","url":null,"abstract":"Declining fertility, overlooked mental health, and reduced life expectancy underscore the urgent need for renewed attention to men’s health. A semen analysis, traditionally used to assess fertility, holds untapped potential as a tool for promoting lifestyle changes and preventing chronic diseases in men. Spermatogenesis is highly sensitive to environmental and lifestyle factors and can be an early indicator of overall health. Disruptions in this process can signal underlying systemic issues and predict long-term health risks, including cardiovascular disease and metabolic disorders. An increasing number of men seek to engage in preconception care, as fertility is closely tied to a man’s sense of masculinity, identity and aspirations for fatherhood. In this context, a semen analysis can be a powerful motivator to encourage healthy behaviours and proactive health management. By incorporating semen analysis into primary care, health care providers can leverage men’s desire for fatherhood as an entry point to discuss broader health concerns, such as mental well-being, nutrition and physical activity. This approach would address immediate reproductive health, and also promote long-term wellness, helping to reduce the burden of chronic disease in men. This Review discusses the association between semen parameters and men’s overall health, describing how these parameters can be influenced by lifestyle and environmental changes. Semen analysis is also presented as a potential tool to motivate men to undertake lifestyle changes to improve their reproductive and overall health.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 10","pages":"687-702"},"PeriodicalIF":14.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-23DOI: 10.1038/s41585-025-01046-2
Nicholas T. H. Farr, Pascal Achenbach, Karl-Dietrich Sievert
Evidence of polypropylene mesh degradation has revealed particle accumulation in surrounding tissues, raising concerns about potential local and systemic immune responses. Associations between polypropylene degradation and autoimmune/autoinflammatory syndrome induced by adjuvants-like symptoms have been made, and vigilant clinical assessment is important, especially in patients with a predisposition for allergy or autoimmune diseases.
{"title":"Effects of degradation-associated polypropylene particles in the surrounding tissue after surgical mesh implantation","authors":"Nicholas T. H. Farr, Pascal Achenbach, Karl-Dietrich Sievert","doi":"10.1038/s41585-025-01046-2","DOIUrl":"10.1038/s41585-025-01046-2","url":null,"abstract":"Evidence of polypropylene mesh degradation has revealed particle accumulation in surrounding tissues, raising concerns about potential local and systemic immune responses. Associations between polypropylene degradation and autoimmune/autoinflammatory syndrome induced by adjuvants-like symptoms have been made, and vigilant clinical assessment is important, especially in patients with a predisposition for allergy or autoimmune diseases.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 12","pages":"791-793"},"PeriodicalIF":14.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：